Skip to main content
We will be working on site updates on Wednesday, July 26. The platform should operate normally for most of the day, except for a 2-4 hour long disruption during maintenance. We apologize for any inconvenience.
18.118.166.161

Tags: Drug product

More tags

All Categories (1-6 of 6)

  1. Continuous Manufacturing to Improve Pharmaceutical Quality: Research Examples and Opportunities

    out of 5 stars 

    | Contributor(s):: Geng Tian

    Continuous manufacturing (CM) of drug substances and drug productsProcess modeling and simulation (M&S) for CM at FDACM research highlightsOpportunities of CM for generic drug productsPharmaceutical Quality Symposium 2023: Quality, Supply Chain & Advanced Manufacturing -...

  2. Common CM Abbreviations - Input Needed

    Forum › defaultsection › general

    Hi all, We are collecting commonly used abbreviations in PCM. This will serve as a useful reference for anyone reviewing PCM materials and studies. We’ve started a list but would like to...

    https://cmkc.usp.org/forum/defaultsection/general/36

  3. Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing

    out of 5 stars 

    | Contributor(s):: Burcham, Christopher L., Florence, Alastair J., Johnson, Martin D.

    The pharmaceutical industry has found new applications for the use of continuous processing for the manufacture of new therapies currently in development. The transformation has been encouraged by regulatory bodies as well as driven by cost reduction, decreased development cycles, access to new...

  4. Characterizing drug product continuous manufacturing residence time distributions of major/minor excipient step changes using near infrared spectroscopy and process parameters

    out of 5 stars 

    | Contributor(s):: Shi, Zhenqi, Manley, Leo

    The material residence time distribution in a continuous manufacturing process can be utilized to develop, design and justify the process control strategy. This paper successfully demonstrates using both major and minor formulation component step changes to determine the system response using...

  5. Achieving Continuous Manufacturing for Final Dosage Formation: Challenges and How to Meet Them

    out of 5 stars 

    | Contributor(s):: Byrn, Stephen, Futran, Maricio, Thomas, Hayden, Jayjock, Eric, Maron, Nicola, Meyer, Robert F., Myerson, Allan S., Thien, Michael P., Trout, Bernhardt L.

    We describe the key issues and possibilities for continuous final dosage formation, otherwise known as downstream processing or drug product manufacturing. A distinction is made between heterogeneous processing and homogeneous processing, the latter of which is expected to add more value to...

  6. A multivariate raw material property database to facilitate drug product development and enable in-silico design of pharmaceutical dry powder processes

    out of 5 stars 

    | Contributor(s):: Van;Snick, B, Dhondt, JPandelaere, K, Bertels, J, Mertens, R, Klingeleers, D, Di, Pretoro, G, Remon, JP, Vervaet, C, De, Beer, T, Vanhoorne, V

    In current study a holistic material characterization approach was proposed and an extensive raw material property database was developed including a wide variety of APIs and excipients with different functionalities. In total 55 different materials were characterized and described by over 100...